Abstract
To report the safety and efficacy of combined cyclophosphamide and rituximab treatment in Saudi children with systemic lupus erythematosus (SLE). Medical records of all children with SLE treated with cyclophosphamide and rituximab between June 2007 and June 2012 at King Faisal Specialist Hospital and Research Center, Riyadh, were reviewed for demographic characteristics, age at diagnosis, concomitant treatments, indication of using rituximab and adverse events during the treatment period. Clinical and serologic response parameters included SLE Disease Activity Index (SLEDAI), complement, anti-ds DNA antibody and ANA levels, and mean daily corticosteroid dose assessed 3 months before combined cyclophosphamide and rituximab infusion course and at 6-month interval afterward. Sixteen patients (13 girls) with refractory SLE treated with cyclophosphamide and rituximab were included. The mean age at onset of SLE was 7.8 + 3.3 years, while the mean age at diagnosis was 8.1 + 3.4 years; the mean disease duration was 4.7 + 3.2 years. All patients were treated with corticosteroid and immunosuppressive drugs. Nephritis (8 patients) was the most frequent indication; other indications included refractory arthritis, thrombocytopenia, severe mucocutaneous lesions and central nervous system involvement. All patients received 2 doses, but 4 required 4–8 extra doses. All patients showed improvement in response parameters. There was significant reduction in SLEDAI (P < 0.0002) and corticosteroid dose (P < 0.005). A total of 4 adverse events were notified; 2 developed infusion-related reactions. One patient had severe soft tissue fungal infection, and other patient had pancreatitis. Our data showed beneficial therapeutic and steroid-sparing effects of rituximab as adjunctive treatment for children with refractory SLE including both renal and extrarenal manifestations. Although rituximab was well tolerated by the majority of patients, it may associated with various adverse events.
Similar content being viewed by others
References
Grammer A, Lipsky P (2003) B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5(Suppl 4):S22–S27
Lipsky P (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764–766
Hoffman R (2004) T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 113:4–13
Vachvanichsanong P, Dissaneewate P, McNeil E (2011) Twenty-two years’ experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries? Arch Dis Child 96:44–49
Huggins J, Burnner H (2006) Targeting B cells in the treatment of childhood-onset systemic lupus erythmatosus. J Pediatr 148:571–573
Thatayatikom A, White A (2006) Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5:18–24
Sfikakis P, Boletis J, Tsokos G (2005) Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17:550–557
Brunner H, Gladman D, Ibañez D, Urowitz M, Silverman E (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556–562
Marks S, Patey S, Brogan S, Hasson N, Pilkington C, Woo P et al (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168–3174
Nwobi O, Abitbol C, Chandar J, Seeherunvong W, Zilleruelo G (2008) Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23:413–419
Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, French Pediatric-Onset SLE Study Group et al (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623–627
El-Hallak M, Binstadt B, Leichtner A, Bennett C, Neufeld E, Fuhlbrigge R et al (2007) Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 150:376–382
Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N et al (1982) The 1982 revised criteria for the classification of the systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Brunner H, Silverman E, To T, To T, Bombardier C, Feldman B (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444
Gillis J, Dall’era M, Gross A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57:538–542
García-Carrasco M, Jiménez-Hernández M, Escárcega R, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M et al (2009) Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 8:343–348
Gunnarsson I, Jonsdottir T (2013) Rituximab treatment in lupus nephritis—where do we stand? Lupus 22:381–389
Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P et al (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–38561
Abdwani R, Mani R (2009) Anti-CD20 monoclonal antibody in acute life threatening hemolytic anemia complicating childhood onset SLE. Lupus 15:460–464
Looney R, Anolik J, Campbell D, Felgar R, Young F, Arend L et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580–2589
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
AlE’ed, A., AlSonbul, A. & Al-Mayouf, S.M. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int 34, 529–533 (2014). https://doi.org/10.1007/s00296-013-2896-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-013-2896-8